The future of health may already be sitting on your arm—small, circular, and constantly collecting data. Once a specialized tool for individuals with Type 1 diabetes, continuous glucose monitors (CGMs) have become the latest frontier in the evolution of personalized health tracking. Worn discreetly on the upper arm or abdomen, these devices continuously measure blood sugar levels in real time, providing users with a dynamic portrait of their body’s metabolic rhythms.
At first glance, CGMs might seem like just another addition to the growing wave of digital health gadgets—Fitbits for the metabolically concerned. But their rapid adoption tells a larger story: one in which the lines between medical necessity and lifestyle optimization are increasingly blurred.
In 2023 alone, sales of CGMs grew by more than 30%, according to market research firm Grand View Research, with the global market expected to surpass $25 billion by 2030. Much of this growth comes not from traditional diabetic populations, but from so-called “health seekers”: wellness influencers, fitness enthusiasts, biohackers, and tech-savvy individuals eager to quantify their physiological responses to everything from coffee to sleep.
This trend reflects a broader shift toward “metabolic awareness”—the idea that our glycemic responses can provide a real-time window into our overall health, well before clinical diagnoses occur. It’s a concept that resonates deeply in a health culture increasingly focused on prevention, personalization, and performance.
“CGMs are no longer just for managing disease,” explains Dr. Kevin Hall, a researcher at the National Institutes of Health. “They’re part of a new wave of data-driven self-care, where individuals use continuous feedback to fine-tune diet, exercise, and lifestyle choices. But that raises important questions about utility, equity, and evidence.”
Indeed, companies like Levels, Nutrisense, and Veri have emerged to capitalize on this space, offering subscription-based CGM services bundled with app interfaces, diet coaching, and personalized health insights. These startups market their products as tools for “glucose optimization,” arguing that even non-diabetics can benefit from monitoring postprandial spikes and minimizing metabolic variability.
Yet the science behind this democratization of CGM use is not fully settled. While glycemic control is undeniably important for health, experts caution against overinterpreting data without proper context. Glucose fluctuations, for example, are normal after meals, and not all spikes are inherently harmful. Misinterpreting this information can lead to unnecessary food restrictions, anxiety, and even orthorexia-like behavior.
“We’re seeing a kind of metabolic perfectionism emerge,” says Dr. Fatima Khan, an endocrinologist at the University of Toronto. “The idea that every glucose rise is dangerous or that there’s one ideal curve to follow isn’t backed by robust clinical evidence. For people with diabetes, CGMs are a lifesaving tool. For others, they may offer insight—but also misinformation.”
There is also a public health dimension to the CGM boom. As more devices flow into the hands of affluent, health-conscious consumers, questions of access and equity loom large. In the United States, where CGMs can cost upwards of $300 a month without insurance, many individuals with Type 2 diabetes—particularly in lower-income communities—remain unable to access these tools. A 2022 study published in JAMA Internal Medicine found that only 20% of Medicare beneficiaries with Type 2 diabetes who could benefit from a CGM were actually using one.
This discrepancy has sparked calls for policy reform. In 2024, the Centers for Medicare and Medicaid Services expanded CGM coverage to include more Type 2 diabetes patients who use insulin, but advocates argue that this still leaves millions uncovered. Meanwhile, commercial expansion into the wellness space may deepen existing inequalities—transforming a critical health tool into a luxury biometric for the well-off.
Still, the cultural momentum behind CGMs is undeniable. They fit neatly into the ethos of the quantified self, in which health is measured, visualized, and optimized through data. In a time when trust in institutions is fragile and medical care often feels reactive, CGMs offer the allure of immediacy and control—a kind of DIY medicine for the digital age.
Whether this trend will lead to better health outcomes or merely more wellness noise remains to be seen. For now, CGMs are emblematic of a larger shift: from population-based guidelines to individual feedback loops; from reactive treatment to proactive tracking; from medicine as authority to medicine as interface.
As we strap sensors to our arms in search of perfect glucose curves, we should also ask: what are we really trying to monitor? And what, in this age of infinite data, might we be missing?
